Veradermics Prices Upsized Public Offering and Private Placement, Raising Over $400 Million
Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative treatments for pattern hair loss, has announced the pricing of an upsized public offering alongside a concurrent private placement, collectively expected to generate significant capital to support its pipeline and operations.
The company confirmed it will offer 3,843,790 shares of its common stock at a public offering price of $100.00 per share. All shares are being issued directly by Veradermics. Based on this pricing, the company anticipates gross proceeds of approximately $384.4 million before accounting for underwriting discounts, commissions, and other associated expenses.
The transaction is expected to close on May 1, 2026, subject to standard closing conditions. In addition, Veradermics has granted underwriters a 30-day option to purchase up to an additional 576,568 shares at the same public offering price, less applicable discounts and commissions. If exercised in full, this option would further increase the total proceeds raised.
Alongside the public offering, Veradermics has entered into a securities purchase agreement for a private placement involving 300,000 pre-funded warrants. These warrants are being sold at a price of $99.99999 per unit, reflecting the public offering price minus a nominal exercise price of $0.00001 per share. The private placement is being made to entities affiliated with Suvretta Capital.
This private transaction is expected to generate approximately $30.0 million in gross proceeds, again before deducting placement agent fees and related expenses. Like the public offering, the private placement is also expected to close on May 1, 2026, subject to customary conditions. Importantly, the completion of the public offering is not dependent on the closing of the private placement.
Several major financial institutions are participating in the offering. Jefferies, Leerink Partners, Citigroup, and Cantor Fitzgerald are acting as joint bookrunning managers. LifeSci Capital is serving as a passive bookrunner, while Needham & Company is acting as lead manager. These firms are also serving as placement agents for the private placement.
The public offering is being conducted under effective registration statements filed with the U.S. Securities and Exchange Commission (SEC). As required by securities regulations, the offering is being made solely through a prospectus, copies of which will be available through the participating financial institutions.
The private placement, however, is being conducted as a transaction exempt from SEC registration under the Securities Act of 1933. As such, the securities issued in this portion of the financing have not been registered and may not be offered or sold in the United States unless they are registered or qualify for an exemption.
Veradermics emphasized that this announcement does not constitute an offer to sell or a solicitation to buy securities in any jurisdiction where such actions would be unlawful prior to registration or qualification under applicable securities laws.
The capital raised through these transactions is expected to strengthen the company’s financial position as it continues advancing its clinical-stage programs targeting pattern hair loss, a condition affecting millions globally. With increasing investor interest and strong backing from institutional participants, Veradermics appears well-positioned to accelerate development efforts and expand its therapeutic portfolio.
About Veradermics
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss. Veradermics aims to develop a focused portfolio of aesthetic dermatology product candidates targeting high-prevalence dermatologic conditions, with potential selective development of medical dermatology product candidates. Its lead program, VDPHL01, is being developed as an oral, non-hormonal treatment for men and women with pattern hair loss, to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform pattern hair loss treatment. VDPHL01 is an oral, extended-release proprietary formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity.
